FDA issued guidance describing: ● the conditions under which it does not intend to take action regarding required stability studies for solid oral products repackaged into unit-dosed containers by commercial pharmaceutical repackaging firms required to register with FDA, and ● the expiration date to assign under those conditions.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
